Roche Holding AG (ROP) AI Stock Analysis

• Market Cap: $240.33B
• Dividend Yield: 2.94%
• Average Volume (3M): 1.25M
• Price to Earnings (P/E): 20.3
• Beta (1Y): 1.29
• Revenue Growth: 4.77%
• EPS Growth: -11.07%
• Country: CH
• Employees: 103,249
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 8.38
• Shares Outstanding: 702,562,700
• 10 Day Avg. Volume: 1,308,571
• 30 Day Avg. Volume: 1,251,256
• PEG Ratio: 0.36
• Price to Book (P/B): 7.73
• Price to Sales (P/S): 4.25
• P/FCF Ratio: 18.55
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 4.32
• Enterprise Value/Gross Profit: 5.87
• Enterprise Value/Ebitda: 11.72
• 1Y Price Target: $350.36
• Price Target Upside: 16.44% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): 20.04
• Revenue Forecast (FY): $62.78B

• Rating: 73 Outperform
• Price Target: CHF336.00 ▲(11.67% Upside)
• Action: Reiterated Date: 03/01/26
• Date: Action: Reiterated 03/01/26

The score is driven primarily by strong underlying profitability and healthy free cash flow, supported by an established upward technical trend. The main constraints are uneven recent growth/margin volatility and a valuation that is not particularly cheap despite the moderate dividend yield.

Positive Factors

High Profitability

Consistently high gross margins and a rebound in net margin indicate durable pricing power and cost control across businesses. This margin profile supports sustained R&D investment and operating leverage, enabling long-term competitiveness and resilience through product cycles.

Robust Free Cash Flow

Strong, recurring FCF provides durable funding for R&D, dividends, and strategic M&A without reliance on capital markets. High FCF as a percent of net income reflects earnings quality and gives management flexibility to prioritize long-term value creation and balance-sheet repair.

Diversified, Recurring Revenue Streams

A two-pronged model (Pharma plus Diagnostics) balances cyclicality: diagnostics consumables provide recurring, annuity-like demand from installed base, while diverse pharma franchises reduce reliance on any single product lifecycle, improving revenue stability over multiple quarters.

Negative Factors

Volatile Revenue Growth

Large swings in top-line growth reduce predictability of earnings and capital allocation. Volatility often reflects product-cycle timing, lumpy milestone or one-off effects, and makes multi-quarter planning harder for investors and management, elevating execution risk.

Sizable Absolute Debt

Although leverage is improving, material absolute debt raises sensitivity to cash-flow shocks or higher interest costs. Elevated debt limits strategic optionality for large-scale M&A or aggressive capital returns and increases risk if future cash generation weakens.

Cash Conversion Friction

Persistent divergence between EBIT and operating cash flow suggests working-capital pressure or timing issues that can reduce liquidity in stress periods. Slower cash conversion constrains near-term reinvestment and raises the chance of needing external financing during downturns.

Roche Holding AG Business Overview & Revenue Model

Company Description

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.

How the Company Makes Money

Roche makes money mainly by selling healthcare products through its Pharmaceuticals and Diagnostics divisions. In Pharmaceuticals, revenue is generated from the sale of patented prescription medicines to hospitals, clinics, pharmacies, and government/insurance-backed healthcare systems, as well as through specialty-care channels; earnings depend on product demand in major therapeutic areas, pricing and reimbursement decisions, and the lifecycle of each medicine (including competition from biosimilars/generics after loss of exclusivity). Roche also generates pharmaceutical-related income from collaborations and licensing arrangements (such as co-development/co-promotion deals, out-licensing of rights, and royalties), and may receive milestone payments where applicable; if specific terms or counterparties are not publicly disclosed in a given context, they are null. In Diagnostics, revenue comes from selling diagnostic instruments/analyzers and, importantly, recurring sales of consumables (test kits, reagents, and other assay materials) used on those installed systems, plus revenue from laboratory automation and software/services tied to diagnostic workflows. Profitability and growth are influenced by the installed base of instruments (which drives repeat consumables demand), menu expansion (new assays), healthcare testing volumes, regulatory approvals, tendering/procurement dynamics, and currency movements given Roche’s global sales footprint. Significant partnerships or factors contributing to earnings beyond the general categories described above: null.

Roche Holding AG Financial Statement Overview

Summary

Strong profitability (gross margins ~69%–74%) and solid cash generation (FCF 14.1B in 2025) support a high-quality profile. Offsetting factors include volatile revenue growth and a notable 2024 margin dip before the 2025 rebound, plus only moderate balance-sheet strength despite improving leverage.

Income Statement

Roche shows strong, resilient profitability with consistently high gross margins (~69%–74%) and healthy net margins (generally ~19%–25%, dipping to ~13% in 2024 before rebounding to ~21% in 2025). Reported revenue growth has been volatile (declines in 2020 and 2023, near-flat 2024, then a sharp +32% in 2025), suggesting uneven top-line momentum. Overall, earnings power looks solid, but the swing in growth and the 2024 margin compression temper the score.

Balance Sheet

Leverage is moderate and has improved recently, with debt-to-equity moving from a higher range (about 1.33 in 2021 and ~1.14 in 2024) down to ~0.94 in 2025, supported by rising equity. Total debt remains sizable (~31.6B in 2025), so balance-sheet risk is not negligible, but the trajectory is constructive versus prior years. Overall balance-sheet strength is adequate for a large pharma company, though not exceptionally conservative.

Cash Flow

Cash generation is strong and consistent: operating cash flow is robust (about 16.1B–20.6B historically; 17.8B in 2025) and free cash flow is healthy (14.1B in 2025) with an 11.9% increase in 2025 after a solid 2024. Free cash flow runs at roughly 71%–79% of net income, indicating good earnings quality. The main weakness is that operating cash flow covers only about ~0.54–0.74 of EBIT across the period (0.64 in 2025), implying working-capital or cash conversion friction versus operating profit.

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Roche Holding AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 300.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:ROP, the sentiment is Negative. The current price of 300.9 is below the 20-day moving average (MA) of 334.05, below the 50-day MA of 339.17, and above the 200-day MA of 286.73, indicating a neutral trend. The MACD of -9.57 indicates Positive momentum. The RSI at 24.88 is Positive, neither overbought nor oversold. The STOCH value of 1.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:ROP.

Roche Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NOVN	78 Outperform	CHF220.01B	18.30	―	3.18%	7.62%	-18.33%
ROP	73 Outperform	$240.33B	20.28	31.98%	2.94%	4.77%	-11.07%
ALC	72 Outperform	CHF29.09B	38.35	4.44%	0.44%	0.39%	-12.46%
SDZ	66 Neutral	CHF26.75B	32.85	2.64%	1.02%	―	―
GALD	63 Neutral	CHF33.37B	75.41	―	0.09%	6.22%	―
LONN	56 Neutral	CHF31.80B	19.54	―	0.75%	5.93%	29.83%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%